Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
1.990
-0.110 (-5.24%)
At close: Mar 28, 2025, 4:00 PM
2.017
+0.027 (1.33%)
Pre-market: Mar 31, 2025, 4:47 AM EDT
Compass Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Compass Therapeutics stock have an average target of 12.43, with a low estimate of 5.00 and a high estimate of 32. The average target predicts an increase of 524.62% from the current stock price of 1.99.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 27, 2025.
Analyst Ratings
The average analyst rating for Compass Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $32 | Strong Buy | Maintains | $32 | +1,508.04% | Feb 27, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $32 | Strong Buy | Maintains | $32 | +1,508.04% | Feb 25, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +503.02% | Feb 24, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $12 | Buy | Initiates | $12 | +503.02% | Feb 19, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | +302.01% | Feb 10, 2025 |
Financial Forecast
Revenue This Year
1.26M
from 850.00K
Increased by 47.65%
Revenue Next Year
45.84M
from 1.26M
Increased by 3,552.43%
EPS This Year
-0.40
from -0.36
EPS Next Year
-0.44
from -0.40
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.9M | 132.7M | 300.3M | ||
| Avg | 1.3M | 45.8M | 138.9M | ||
| Low | n/a | 13.5M | 45.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,419.4% | 10,469.7% | 555.2% | ||
| Avg | 47.6% | 3,552.4% | 202.9% | ||
| Low | - | 973.9% | -0.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.20 | 0.33 | 1.25 | ||
| Avg | -0.40 | -0.44 | 0.19 | ||
| Low | -0.67 | -1.16 | -0.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.